Literature DB >> 18755563

Identification, synthesis, isolation and spectral characterization of potential impurities of montelukast sodium.

M Saravanan1, K Siva Kumari, P Pratap Reddy, M N Naidu, J Moses Babu, Alok Kumar Srivastava, T Lakshmi Kumar, B V V N Chandra Sekhar, Bollikonda Satyanarayana.   

Abstract

During the process development of montelukast sodium, three polar impurities and one non-polar impurity with respect to montelukast sodium were detected by simple reverse phase high-performance liquid chromatography (HPLC). Initially, all the four impurities were identified by the liquid chromatography-mass spectrometry (LC-MS) data and out of four impurities, three have been prepared by the synthetic method and remaining one is isolated by preparative HPLC. Based on the spectral data (IR, (1)H NMR, (13)C NMR and MS), the structure of these impurities 1-4 were characterised as 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropane acetamide (impurity-1), {1-[1-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-(2-isopropenyl-phenyl)-propylsulfanylmethyl]-cyclopropyl}-acetic acid (impurity-2), 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethyl]phenyl-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (impurity-3) and 1-[[[(1R)-1-[3-[(1E)-2-(2-quinolinyl)ethenyl]phenyl-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (impurity-4).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18755563     DOI: 10.1016/j.jpba.2008.07.007

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  Development and Validation of a RP-HPLC Method for Estimation of Montelukast Sodium in Bulk and in Tablet Dosage Form.

Authors:  R M Singh; P K Saini; S C Mathur; G N Singh; B Lal
Journal:  Indian J Pharm Sci       Date:  2010-03       Impact factor: 0.975

2.  Method development and validation of montelukast in human plasma by HPLC coupled with ESI-MS/MS: application to a bioequivalence study.

Authors:  Balasekhara Reddy Challa; Bahlul Z Awen; Babu Rao Chandu; Mukkanti Khagga; Chandrasekhar Bannoth Kotthapalli
Journal:  Sci Pharm       Date:  2010-06-04

3.  Development and validation of LC/MS/MS method for the simultaneous determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study.

Authors:  Essam Ezzeldin; Nisreen F Abo-Talib; Marwa H Tammam; Abdelaaty A Shahat
Journal:  Chem Cent J       Date:  2014-03-11       Impact factor: 4.215

4.  Synthesis of Copper Oxide-Based Nanoformulations of Etoricoxib and Montelukast and Their Evaluation through Analgesic, Anti-Inflammatory, Anti-Pyretic, and Acute Toxicity Activities.

Authors:  Sulaiman Sulaiman; Shabir Ahmad; Syeda Sohaila Naz; Sara Qaisar; Sayyar Muhammad; Amal Alotaibi; Riaz Ullah
Journal:  Molecules       Date:  2022-02-21       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.